ADHD Therapeutics Market Research Report – Segmented by Product Type (Stimulants and Non-Stimulants); By Age Group (Pediatric Population, Adolescent Population, and Adult Population); By Treatment by Psychotherapy (Behaviour Therapy, Cognitive Behavioral Therapy, Interpersonal Psychotherapy, Family Therapy); By Training (Parent Management Training, Social Skills Training, School-based Intervention); and Region - Size, Share, Growth Analysis | Forecast (2023 – 2030)

ADHD Therapeutics Market Size (2023-2030)

The Global ADHD Therapeutics Market was estimated to be worth USD 25.18 Billion in 2022 and is anticipated to reach a value of USD 43.59 Billion by 2030, growing at a fast CAGR of 7.1% during the forecast period 2023-2030.


The ADHD (Attention-Deficit/Hyperactivity Disorder) therapeutics market refers to the pharmaceutical products and treatment options available for managing symptoms associated with ADHD. ADHD is a neurodevelopmental disorder characterized by persistent patterns of inattention, hyperactivity, and impulsivity that can significantly impact a person's daily functioning and quality of life. ADHD therapeutics aim to alleviate the core symptoms of the disorder including difficulties in sustaining attention, hyperactivity, and impulsivity. These treatments can help individuals with ADHD improve their focus, concentration, and impulse control, allowing them to better manages their symptoms and enhance their overall functioning.

Global ADHD Therapeutics Market Drivers:

The Increasing Prevalence of ADHD is fuelling ADHD therapeutics market growth.

The rising prevalence of ADHD globally is a significant driver for the market. The disorder affects children, adolescents, and adults, with estimates suggesting that around 5-7% of children and 2-5% of adults worldwide are diagnosed with ADHD. The growing awareness and diagnosis of the condition contribute to the demand for effective therapeutic options.

The rising research and development sector is boosting the growth of the ADHD therapeutics area.

Continuous research and development efforts in the field of ADHD therapeutics drive market growth. Pharmaceutical companies invest in developing new medications, formulations, and delivery systems to improve treatment efficacy, safety, and patient compliance. Ongoing research helps expand the range of available options and drives innovation in the market.

Pharmaceutical companies are investing in the development of non-stimulant medications and extended-release formulations as an alternative treatment option for ADHD. For instance, the non-stimulant medication viloxazine has undergone clinical trials and has shown promising results in improving ADHD symptoms. Additionally, there is a growing acceptance and recognition of the impact of ADHD on individuals' lives, leading to an increased willingness to seek treatment. As ADHD can significantly affect academic, occupational, and social functioning, individuals and their families are seeking therapeutic options to manage symptoms and improve overall quality of life.

Global ADHD Therapeutics Market Challenges:

Side Effects and Safety Concerns may impede market growth.

Certain ADHD medications, particularly stimulant medications, can have side effects such as decreased appetite, sleep disturbances, and increased heart rate. These side effects can impact patient compliance and treatment adherence. Safety concerns related to long-term use and potential risks may also affect the willingness of patients and caregivers to opt for pharmacological interventions.

Regulatory and Intellectual Property Challenges may restrain market growth.

The process of obtaining regulatory approvals for new ADHD medications can be complex and time-consuming. Intellectual property challenges, such as patent disputes and exclusivity periods, can impact market competition and the availability of generic alternatives, potentially limiting treatment options and affordability. While ADHD medications are available in different formulations and dosages, finding the most effective medication and dosage for each individual can be a trial-and-error process. The lack of personalized treatment options based on individual characteristics, such as genetics or specific symptom profiles, may hinder treatment efficacy and patient outcomes.

COVID-19 Impact on the Global ADHD Therapeutics Market:

The COVID-19 pandemic had negative impacts on the ADHD therapeutics market. The pandemic has caused disruptions in healthcare services, including reduced access to clinics, delayed appointments, and decreased in-person evaluations. These disruptions have affected the diagnosis and treatment of ADHD, potentially leading to delays in initiating or modifying therapeutic interventions. The global supply chain disruptions caused by the pandemic have affected the manufacturing and distribution of medications, including ADHD therapeutics. This has led to potential shortages or delays in the availability of certain medications, impacting patient access to treatment.

Economic uncertainties and financial constraints resulting from the pandemic have affected healthcare systems and individuals' ability to afford medications and healthcare services. Reduced financial resources may impact the demand for ADHD therapeutics and treatment adherence.

 The pandemic has had a significant impact on mental health globally, including increased stress, anxiety, and depression. The mental health burden may overshadow the recognition and management of ADHD symptoms, potentially affecting the demand for ADHD therapeutics.




Market Size Available

2022 - 2030

Base Year


Forecast Period

2023 - 2030



Segments Covered

By Product Type, Age Group, Treatment by Psychotherapy, Training,  and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regional Scope

North America, Europe, APAC, Latin America, Middle East & Africa

Key Companies Profiled

Eli Lilly and Company, Novartis AG, Shire (now part of Takeda Pharmaceutical Company Limited), Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson), Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., UCB S.A., Mallinckrodt Pharmaceuticals, Impax Laboratories (now part of Amneal Pharmaceuticals)

Global ADHD Therapeutics Market Segmentation: By Product Type

  • Stimulant

    • Methylphenidate

    • Dextroamphetamine

    • Amphetamine

    • Dexmethylphenidate

  • Non-Stimulants

    • Atomoxetine

    • Bupropion

    • Guanfacine

Stimulant medications are the most widely prescribed and commonly used treatment for ADHD. They work by increasing the levels of neurotransmitters such as dopamine and norepinephrine in the brain, which help improve attention, focus, and impulse control. Stimulant medications have traditionally dominated the ADHD therapeutics market due to their proven efficacy and long-standing use. They are widely prescribed for both pediatric and adult patients, contributing to a significant market size in terms of revenue.

Non-stimulant medications are an alternative option for individuals who cannot tolerate or do not respond well to stimulant medications. They work by targeting different neurotransmitters and brain pathways involved in ADHD. While stimulant medications are more commonly prescribed, the non-stimulant segment has gained prominence in recent years and is anticipated to have faster growth.

Global ADHD Therapeutics Market Segmentation: By Age Group

  • Pediatric Population

  • Adolescent Population

  • Adult Population

The pediatric population segment includes children who are diagnosed with ADHD and is the largest segment. ADHD is often diagnosed during childhood, and children make up a significant portion of the population affected by this condition. Adolescents with ADHD make up another segment of the market. This age group typically consists of individuals between the ages of 12 to 17. The adult segment of the ADHD therapeutics market encompasses individuals aged 18 and above who have either been diagnosed with ADHD during adulthood or have had a diagnosis since childhood that has persisted into adulthood.  The adult population segment is projected to grow at a faster rate in the coming years in the ADHD therapeutics market.

Global ADHD Therapeutics Market Segmentation: By Treatment by Psychotherapy

  • Behaviour Therapy

  • Cognitive Behavioral Therapy

  • Interpersonal Psychotherapy

  • Family Therapy

Based on a treatment by psychotherapy, behavior therapy held the highest market share in 2022 since it is the most commonly used method for ADHD. It is helpful in the treatment that helps in improving the patient’s self-esteem and is effective in treating ADHD.

Global ADHD Therapeutics Market Segmentation: By Training

  • Parent Management Training

  • Social Skills Training

  • School-based Intervention

Based on the training type, parent management training is the most popular segment and is anticipated to hold the highest market share during the forecast period as well. This majority can be majorly attributed to the rising awareness among the parents.

Global ADHD Therapeutics Market Segmentation: By Region

  • North America

  • Europe

  • Asia Pacific

  • South America

  • Middle East and Africa

North America has a significant market share in the ADHD therapeutics market, driven by factors such as the high prevalence of ADHD, well-established healthcare infrastructure, advanced research and development activities, and a favorable regulatory environment. Europe is a prominent market for ADHD therapeutics, supported by factors such as increasing awareness and diagnosis of ADHD, government initiatives, and the presence of key market players. The market for ADHD therapeutics in this region is growing rapidly due to factors such as a large population base, increasing awareness of ADHD, rising healthcare expenditure, and improving access to healthcare services.

Global ADHD Therapeutics Market Key Players:

  1. Eli Lilly and Company

  2. Novartis AG

  3. Shire (now part of Takeda Pharmaceutical Company Limited)

  4. Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson)

  5. Pfizer Inc.

  6. GlaxoSmithKline plc

  7. Teva Pharmaceutical Industries Ltd.

  8. UCB S.A.

  9. Mallinckrodt Pharmaceuticals

  10. Impax Laboratories (now part of Amneal Pharmaceuticals)

Chapter 1. ADHD Therapeutics Market – Scope & Methodology
1.1    Market Segmentation
1.2    Assumptions
1.3    Research Methodology
1.4    Primary Sources
1.5    Secondary Sources
Chapter 2. ADHD Therapeutics Market – Executive Summary
2.1    Market Size & Forecast – (2023 – 2030) ($M/$Bn)
2.2    Key Trends & Insights
2.3    COVID-19 Impact Analysis
            2.3.1    Impact during 2023 – 2030
            2.3.2    Impact on Supply – Demand
Chapter 3. ADHD Therapeutics Market – Competition Scenario
3.1    Market Share Analysis
3.2    Product Benchmarking
3.3    Competitive Strategy & Development Scenario
3.4    Competitive Pricing Analysis
3.5    Supplier - Distributor Analysis
Chapter 4. ADHD Therapeutics Market - Entry Scenario
4.1     Case Studies – Start-up/Thriving Companies
4.2     Regulatory Scenario - By Region
4.3    Customer Analysis
4.4     Porter's Five Force Model
            4.4.1     Bargaining Power of Suppliers
            4.4.2     Bargaining Powers of Customers
            4.4.3    Threat of New Entrants
            4.4.4    .Rivalry among Existing Players
            4.4.5    Threat of Substitutes
Chapter 5. ADHD Therapeutics Market - Landscape
5.1     Value Chain Analysis – Key Stakeholders Impact Analysis
5.2    Market Drivers
5.3    Market Restraints/Challenges
5.4    Market Opportunities 
Chapter 6. ADHD Therapeutics Market - By Product Type
6.1    Stimulant
            6.1.1    Methylphenidate
            6.1.2    Dextroamphetamine
            6.1.3    Amphetamine
            6.1.4    Dexmethylphenidate
6.2    Non-Stimulants
            6.2.1    Atomoxetine
            6.2.2    Bupropion
            6.2.3    Guanfacine
Chapter 7. ADHD Therapeutics Market - By Age Group
7.1    Pediatric Population
7.2    Adolescent Population
7.3    Adult Population
Chapter 8. ADHD Therapeutics Market - By Treatment by Psychotherapy
8.1    Behaviour Therapy
8.2    Cognitive Behavioral Therapy
8.3    Interpersonal Psychotherapy
8.4    Family Therapy
Chapter 9. ADHD Therapeutics Market - By Training
9.1    Parent Management Training
9.2    Social Skills Training
9.3    School-based Intervention
Chapter 10. ADHD Therapeutics Market – By Region
10.1    North America
10.2    Europe
10.3    Asia-Pacific
10.4    Latin America
10.5    The Middle East
10.6    Africa
Chapter 11. ADHD Therapeutics Market – Key Players
11.1    Eli Lilly and Company
11.2    Novartis AG
11.3    Shire (now part of Takeda Pharmaceutical Company Limited)
11.4    Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson)
11.5    Pfizer Inc.
11.6    GlaxoSmithKline plc
11.7    Teva Pharmaceutical Industries Ltd.
11.8    UCB S.A.
11.9    Mallinckrodt Pharmaceuticals
11.10    Impax Laboratories (now part of Amneal Pharmaceuticals)


Download Sample

The field with (*) is required.

Choose License Type









Frequently Asked Questions

The Global ADHD Therapeutics Market was estimated to be worth USD 25.18 Billion in 2022 and is anticipated to reach a value of USD 43.59 Billion by 2030, growing at a fast CAGR of 7.1% during the forecast period 2023-2030.

The global ADHD Therapeutics market is driven by factors such as increasing cases of ADHD, research, and development, and increasing treatment-seeking behavior among individuals.

Stimulants and Non-Stimulants are segments under the Global ADHD Therapeutics Market by product type.

North America dominates the market in Global ADHD Therapeutics Market.

Asia-Pacific is the fastest-growing region in the Global ADHD Therapeutics Market.

Analyst Support

Every order comes with Analyst Support.


We offer customization to cater your needs to fullest.

Verified Analysis

We value integrity, quality and authenticity the most.